1724 related articles for article (PubMed ID: 26129684)
41. Different IgG-subclass distributions after whole-cell and acellular pertussis infant primary vaccinations in healthy and pertussis infected children.
Hendrikx LH; Schure RM; Oztürk K; de Rond LG; de Greeff SC; Sanders EA; Berbers GA; Buisman AM
Vaccine; 2011 Sep; 29(40):6874-80. PubMed ID: 21803088
[TBL] [Abstract][Full Text] [Related]
42. Proteomics of Bordetella pertussis whole-cell and acellular vaccines.
Möller J; Kraner ME; Burkovski A
BMC Res Notes; 2019 Jun; 12(1):329. PubMed ID: 31182148
[TBL] [Abstract][Full Text] [Related]
43. A randomized comparison of reactogenicity and immunogenicity of two whole-cell pertussis vaccines.
Steinhoff MC; Reed GF; Decker MD; Edwards KM; Englund JA; Pichichero ME; Rennels MB; Anderson EL; Deloria MA; Meade BD
Pediatrics; 1995 Sep; 96(3 Pt 2):567-70. PubMed ID: 7659477
[TBL] [Abstract][Full Text] [Related]
44. A novel method for evaluating natural and vaccine induced serological responses to Bordetella pertussis antigens.
Berbers GA; van de Wetering MS; van Gageldonk PG; Schellekens JF; Versteegh FG; Teunis PF
Vaccine; 2013 Aug; 31(36):3732-8. PubMed ID: 23742995
[TBL] [Abstract][Full Text] [Related]
45. Intranasal Immunization with Acellular Pertussis Vaccines Results in Long-Term Immunity to Bordetella pertussis in Mice.
Wolf MA; Boehm DT; DeJong MA; Wong TY; Sen-Kilic E; Hall JM; Blackwood CB; Weaver KL; Kelly CO; Kisamore CA; Bitzer GJ; Bevere JR; Barbier M; Damron FH
Infect Immun; 2021 Feb; 89(3):. PubMed ID: 33318136
[No Abstract] [Full Text] [Related]
46. Construction and preliminary immunobiological characterization of a novel, non-reverting, intranasal live attenuated whooping cough vaccine candidate.
Cornford-Nairns R; Daggard G; Mukkur T
J Microbiol Biotechnol; 2012 Jun; 22(6):856-65. PubMed ID: 22573165
[TBL] [Abstract][Full Text] [Related]
47. Serological responses to infection with B. pertussis.
Giammanco A; Taormina S; Genovese M; Mangiaracina G; Giammanco G; Chiarini A
Dev Biol Stand; 1997; 89():213-20. PubMed ID: 9272353
[TBL] [Abstract][Full Text] [Related]
48. Bordetella pertussis isolates in Finland: serotype and fimbrial expression.
Heikkinen E; Xing DK; Olander RM; Hytönen J; Viljanen MK; Mertsola J; He Q
BMC Microbiol; 2008 Sep; 8():162. PubMed ID: 18816412
[TBL] [Abstract][Full Text] [Related]
49. Induction of Bordetella pertussis-specific immune memory by DTPa vaccines.
Morel S; Denoël P; Godfroid F; Cortvrindt C; Vanderheyde N; Poolman J
Vaccine; 2011 Apr; 29(18):3449-55. PubMed ID: 21382483
[TBL] [Abstract][Full Text] [Related]
50. Immunoblot analysis of humoral immune responses following infection with Bordetella pertussis or immunization with diphtheria-tetanus-pertussis vaccine.
Redd SC; Rumschlag HS; Biellik RJ; Sanden GN; Reimer CB; Cohen ML
J Clin Microbiol; 1988 Jul; 26(7):1373-7. PubMed ID: 2900846
[TBL] [Abstract][Full Text] [Related]
51. Cell-mediated immunity and antibody responses to Bordetella pertussis antigens in children with a history of pertussis infection and in recipients of an acellular pertussis vaccine.
Ausiello CM; Lande R; Urbani F; Di Carlo B; Stefanelli P; Salmaso S; Mastrantonio P; Cassone A
J Infect Dis; 2000 Jun; 181(6):1989-95. PubMed ID: 10837180
[TBL] [Abstract][Full Text] [Related]
52. Antibody responses in adult and neonatal BALB/c mice to immunization with novel Bordetella pertussis vaccine formulations.
Gracia A; Polewicz M; Halperin SA; Hancock RE; Potter AA; Babiuk LA; Gerdts V
Vaccine; 2011 Feb; 29(8):1595-604. PubMed ID: 21215343
[TBL] [Abstract][Full Text] [Related]
53. Immunologic and epidemiologic experience of vaccination with a monocomponent pertussis toxoid vaccine.
Taranger J; Trollfors B; Bergfors E; Knutsson N; Lagergård T; Schneerson R; Robbins JB
Pediatrics; 2001 Dec; 108(6):E115. PubMed ID: 11731642
[TBL] [Abstract][Full Text] [Related]
54. Evaluation of Adenylate Cyclase Toxoid Antigen in Acellular Pertussis Vaccines by Using a Bordetella pertussis Challenge Model in Mice.
Boehm DT; Hall JM; Wong TY; DiVenere AM; Sen-Kilic E; Bevere JR; Bradford SD; Blackwood CB; Elkins CM; DeRoos KA; Gray MC; Cooper CG; Varney ME; Maynard JA; Hewlett EL; Barbier M; Damron FH
Infect Immun; 2018 Oct; 86(10):. PubMed ID: 30012638
[No Abstract] [Full Text] [Related]
55. Immune responses to pertussis vaccines and disease.
Edwards KM; Berbers GA
J Infect Dis; 2014 Apr; 209 Suppl 1():S10-5. PubMed ID: 24158958
[TBL] [Abstract][Full Text] [Related]
56. Cytokine and antibody profiles in 1-year-old children vaccinated with either acellular or whole-cell pertussis vaccine during infancy.
Dirix V; Verscheure V; Goetghebuer T; Hainaut M; Debrie AS; Locht C; Mascart F
Vaccine; 2009 Oct; 27(43):6042-7. PubMed ID: 19665604
[TBL] [Abstract][Full Text] [Related]
57. Seroprevalence of IgG antibodies against Bordetella pertussis in healthy individuals aged 4-24 years in Turkey.
Cevik M; Beyazova U; Aral AL; Duyan Camurdan A; Ozkan S; Sahin F; Aybay C
Clin Microbiol Infect; 2008 Apr; 14(4):388-90. PubMed ID: 18190581
[TBL] [Abstract][Full Text] [Related]
58. [Detection of Bordetella pertussis infection by culture, real-time polymerase chain reaction and serologic tests among children with prolonged cough].
Gürsel D; Aslan A; Sönmez C; Koturoğlu G; Cöplü N; Kurugöl Z; Aydemir S
Mikrobiyol Bul; 2012 Apr; 46(2):211-24. PubMed ID: 22639310
[TBL] [Abstract][Full Text] [Related]
59. Whole-cell and acellular pertussis vaccines.
Wintermeyer SM; Nahata MC; Kyllonen KS
Ann Pharmacother; 1994; 28(7-8):925-39. PubMed ID: 7949515
[TBL] [Abstract][Full Text] [Related]
60. Comparison of 13 acellular pertussis vaccines: overview and serologic response.
Edwards KM; Meade BD; Decker MD; Reed GF; Rennels MB; Steinhoff MC; Anderson EL; Englund JA; Pichichero ME; Deloria MA
Pediatrics; 1995 Sep; 96(3 Pt 2):548-57. PubMed ID: 7659475
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
